APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted Drugs for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Targeted Drugs for Multiple Sclerosis Market Analysis and Forecast 2026-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchTargeted Drugs for Multiple Sclerosis Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted Drugs for Multiple Sclerosis Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Targeted Drugs for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted Drugs for Multiple Sclerosis Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted Drugs for Multiple Sclerosis Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Targeted Drugs for Multiple Sclerosis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Targeted Drugs for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Targeted Drugs for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Targeted Drugs for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Targeted Drugs for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Targeted Drugs for Multiple Sclerosis include NOVARTIS, Roche, Biogen, Sanofi, Janssen and Bristol-Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Targeted Drugs for Multiple Sclerosis, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Targeted Drugs for Multiple Sclerosis, also provides the revenue of main regions and countries. Of the upcoming market potential for Targeted Drugs for Multiple Sclerosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Targeted Drugs for Multiple Sclerosis revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Targeted Drugs for Multiple Sclerosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Targeted Drugs for Multiple Sclerosis revenue, projected growth trends, production technology, application and end-user industry.

Targeted Drugs for Multiple Sclerosis Segment by Company

NOVARTIS

Roche

Biogen

Sanofi

Janssen

Bristol-Myers Squibb

Targeted Drugs for Multiple Sclerosis Segment by Type

Oral

Injection

Targeted Drugs for Multiple Sclerosis Segment by Application

Hospital

Clinic

Other

Targeted Drugs for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Targeted Drugs for Multiple Sclerosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Targeted Drugs for Multiple Sclerosis company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Targeted Drugs for Multiple Sclerosis revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Targeted Drugs for Multiple Sclerosis Industry Trends Table 9. Targeted Drugs for Multiple Sclerosis Industry Drivers Table 10. Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges Table 11. Targeted Drugs for Multiple Sclerosis Industry Restraints Table 12. Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Targeted Drugs for Multiple Sclerosis Market Share by Region (2021-2026) Table 15. Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Targeted Drugs for Multiple Sclerosis Market Share by Region (2027-2032) Table 17. Global Targeted Drugs for Multiple Sclerosis Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Players (2021-2026) Table 19. Global Targeted Drugs for Multiple Sclerosis Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Targeted Drugs for Multiple Sclerosis Key Players Headquarters & Area Served Table 21. Global Targeted Drugs for Multiple Sclerosis Players, Product Type & Application Table 22. Global Targeted Drugs for Multiple Sclerosis Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Targeted Drugs for Multiple Sclerosis by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Targeted Drugs for Multiple Sclerosis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Type (2021-2026) Table 29. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Type (2027-2032) Table 30. Global Targeted Drugs for Multiple Sclerosis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Application (2021-2026) Table 34. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Application (2027-2032) Table 35. NOVARTIS Company Information Table 36. NOVARTIS Business Overview Table 37. NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio Table 39. NOVARTIS Recent Development Table 40. Roche Company Information Table 41. Roche Business Overview Table 42. Roche Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Roche Targeted Drugs for Multiple Sclerosis Product Portfolio Table 44. Roche Recent Development Table 45. Biogen Company Information Table 46. Biogen Business Overview Table 47. Biogen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio Table 49. Biogen Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio Table 54. Sanofi Recent Development Table 55. Janssen Company Information Table 56. Janssen Business Overview Table 57. Janssen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio Table 59. Janssen Recent Development Table 60. Bristol-Myers Squibb Company Information Table 61. Bristol-Myers Squibb Business Overview Table 62. Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio Table 64. Bristol-Myers Squibb Recent Development Table 65. North America Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 66. North America Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 67. North America Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 68. North America Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 69. North America Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Targeted Drugs for Multiple Sclerosis Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (US$ Million) & (2027-2032) Table 79. China Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 80. China Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 81. China Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 82. China Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia Targeted Drugs for Multiple Sclerosis Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Targeted Drugs for Multiple Sclerosis Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia Targeted Drugs for Multiple Sclerosis Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Targeted Drugs for Multiple Sclerosis Image Figure 2. Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted Drugs for Multiple Sclerosis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. Global Targeted Drugs for Multiple Sclerosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Targeted Drugs for Multiple Sclerosis Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Targeted Drugs for Multiple Sclerosis Market Size (US$ Million) & (2021-2032) Figure 12. Global Targeted Drugs for Multiple Sclerosis Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Targeted Drugs for Multiple Sclerosis Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Targeted Drugs for Multiple Sclerosis Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Targeted Drugs for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Type (2021-2032) Figure 19. Global Targeted Drugs for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Application (2021-2032) Figure 22. North America Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032) Figure 24. North America Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032) Figure 25. North America Targeted Drugs for Multiple Sclerosis Revenue Share by Country (2021-2032) Figure 26. United States Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032) Figure 31. Europe Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032) Figure 32. Europe Targeted Drugs for Multiple Sclerosis Revenue Share by Country (2021-2032) Figure 33. Germany Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032) Figure 43. China Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032) Figure 44. Asia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032) Figure 46. Asia Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032) Figure 47. Asia Targeted Drugs for Multiple Sclerosis Revenue Share by Region (2021-2032) Figure 48. Japan Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032) Figure 56. SAMEA Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032) Figure 57. SAMEA Targeted Drugs for Multiple Sclerosis Revenue Share by Country (2021-2032) Figure 58. Brazil Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Targeted Drugs for Multiple Sclerosis Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • NOVARTIS
  • Roche
  • Biogen
  • Sanofi
  • Janssen
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Targeted Drugs for Multiple Sclerosis Market by Type
  3. 1.2.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.3 Targeted Drugs for Multiple Sclerosis Market by Application
  7. 1.3.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Targeted Drugs for Multiple Sclerosis Market Dynamics
  1. 2.1 Targeted Drugs for Multiple Sclerosis Industry Trends
  2. 2.2 Targeted Drugs for Multiple Sclerosis Industry Drivers
  3. 2.3 Targeted Drugs for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Targeted Drugs for Multiple Sclerosis Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Targeted Drugs for Multiple Sclerosis Market Perspective (2021-2032)
  2. 3.2 Global Targeted Drugs for Multiple Sclerosis Growth Trends by Region
  3. 3.2.1 Global Targeted Drugs for Multiple Sclerosis Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2021-2026)
  5. 3.2.3 Global Targeted Drugs for Multiple Sclerosis Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Players
  2. 4.1.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Players (2021-2026)
  3. 4.1.2 Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Targeted Drugs for Multiple Sclerosis Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Targeted Drugs for Multiple Sclerosis Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Targeted Drugs for Multiple Sclerosis Key Players Headquarters & Area Served
  7. 4.4 Global Targeted Drugs for Multiple Sclerosis Players, Product Type & Application
  8. 4.5 Global Targeted Drugs for Multiple Sclerosis Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Targeted Drugs for Multiple Sclerosis Market CR5 and HHI
  11. 4.6.3 2025 Targeted Drugs for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
5 Targeted Drugs for Multiple Sclerosis Market Size by Type
  1. 5.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 5.3 Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Type (2021-2032)
6 Targeted Drugs for Multiple Sclerosis Market Size by Application
  1. 6.1 Global Targeted Drugs for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  3. 6.3 Global Targeted Drugs for Multiple Sclerosis Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 NOVARTIS
  2. 7.1.1 NOVARTIS Company Information
  3. 7.1.2 NOVARTIS Business Overview
  4. 7.1.3 NOVARTIS Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  5. 7.1.4 NOVARTIS Targeted Drugs for Multiple Sclerosis Product Portfolio
  6. 7.1.5 NOVARTIS Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Targeted Drugs for Multiple Sclerosis Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Biogen
  14. 7.3.1 Biogen Company Information
  15. 7.3.2 Biogen Business Overview
  16. 7.3.3 Biogen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biogen Targeted Drugs for Multiple Sclerosis Product Portfolio
  18. 7.3.5 Biogen Recent Developments
  19. 7.4 Sanofi
  20. 7.4.1 Sanofi Company Information
  21. 7.4.2 Sanofi Business Overview
  22. 7.4.3 Sanofi Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi Targeted Drugs for Multiple Sclerosis Product Portfolio
  24. 7.4.5 Sanofi Recent Developments
  25. 7.5 Janssen
  26. 7.5.1 Janssen Company Information
  27. 7.5.2 Janssen Business Overview
  28. 7.5.3 Janssen Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Janssen Targeted Drugs for Multiple Sclerosis Product Portfolio
  30. 7.5.5 Janssen Recent Developments
  31. 7.6 Bristol-Myers Squibb
  32. 7.6.1 Bristol-Myers Squibb Company Information
  33. 7.6.2 Bristol-Myers Squibb Business Overview
  34. 7.6.3 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb Targeted Drugs for Multiple Sclerosis Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Targeted Drugs for Multiple Sclerosis Revenue (2021-2032)
  2. 8.2 North America Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 8.2.1 North America Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026)
  4. 8.2.2 North America Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032)
  5. 8.3 North America Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032)
  6. 8.4 North America Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 8.4.1 North America Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026)
  8. 8.4.2 North America Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032)
  9. 8.5 North America Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032)
  10. 8.6 North America Targeted Drugs for Multiple Sclerosis Revenue by Country
  11. 8.6.1 North America Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026)
  13. 8.6.3 North America Targeted Drugs for Multiple Sclerosis Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Targeted Drugs for Multiple Sclerosis Revenue (2021-2032)
  2. 9.2 Europe Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 9.2.1 Europe Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026)
  4. 9.2.2 Europe Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032)
  5. 9.3 Europe Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032)
  6. 9.4 Europe Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 9.4.1 Europe Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026)
  8. 9.4.2 Europe Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032)
  9. 9.5 Europe Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032)
  10. 9.6 Europe Targeted Drugs for Multiple Sclerosis Revenue by Country
  11. 9.6.1 Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026)
  13. 9.6.3 Europe Targeted Drugs for Multiple Sclerosis Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Targeted Drugs for Multiple Sclerosis Revenue (2021-2032)
  2. 10.2 China Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 10.2.1 China Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026)
  4. 10.2.2 China Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032)
  5. 10.3 China Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032)
  6. 10.4 China Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 10.4.1 China Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026)
  8. 10.4.2 China Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032)
  9. 10.5 China Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Targeted Drugs for Multiple Sclerosis Revenue (2021-2032)
  2. 11.2 Asia Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 11.2.1 Asia Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026)
  4. 11.2.2 Asia Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032)
  5. 11.3 Asia Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032)
  6. 11.4 Asia Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 11.4.1 Asia Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026)
  8. 11.4.2 Asia Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032)
  9. 11.5 Asia Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032)
  10. 11.6 Asia Targeted Drugs for Multiple Sclerosis Revenue by Country
  11. 11.6.1 Asia Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026)
  13. 11.6.3 Asia Targeted Drugs for Multiple Sclerosis Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Targeted Drugs for Multiple Sclerosis Revenue (2021-2032)
  2. 12.2 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Type (2027-2032)
  5. 12.3 SAMEA Targeted Drugs for Multiple Sclerosis Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Application (2027-2032)
  9. 12.5 SAMEA Targeted Drugs for Multiple Sclerosis Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country
  11. 12.6.1 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Targeted Drugs for Multiple Sclerosis Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst